News from Nashville & around the world
A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75. NYT > Health
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost. NYT > Health
A man in his early 40s showed physical signs of the illness, but didn’t develop symptoms until he was nearly 70 because of a protective gene. NYT > Health
Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows. U.S. News
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.” NYT > Health
PHOTO: Members of the supermere discovery team include (front row from left) Qi Liu, PhD, Robert Coffey, MD, Qin Zhang, PhD, and (back row from left) James Higginbotham, PhD; Dennis Jeppesen, PhD; and Jeffrey Franklin,…